Effects of pre-analytical variables on the anti-activated factor X chromogenic assay when monitoring unfractionated heparin and low molecular weight heparin anticoagulation.
McGlasson DL, Kaczor DA, Krasuski RA, Campbell CL, Kostur MR, Adinaro JT
Purpose
Conclusion
Studies (1)
Purpose
The purpose of this study was to determine if the use of different anticoagulants or the ratio of blood to anticoagulant during specimen collection affects anti-FXa assay results or aPTT for patients receiving UFH and LMWH therapy. Plasma specimens were stored at -70 degrees C prior to analysis.
Summary of Findings
Specimens from UFH patients collected into 3.8% sodium citrate with ratio of 6:1 (blood: anticoagulant) showed a statistically significant increase in aPTT (p=0.06) with an average time of 127.2 s versus 105.4 s when specimens were collected using standard methods (3.2% sodium citrate and a 9:1 blood to anticoagulant ratio). However, some UFH specimens had aPTT times over 300 s which could have skewed the mean. No other combinations of anticoagulant and blood/anticoagulant ratio resulted in statistically significant differences in aPTT for patients receiving UFH or LMWH therapy. There were several aPTT times which did not correlate with the amount of heparin, indicating an effect of other variables besides heparin on aPTT. Importantly, neither blood to anticoagulant ratio nor type of anticoagulant affected anti-FXa assay results for either heparin therapy suggesting this assay is better suited for monitoring heparin patients.
Biospecimens
FluidBloodFluidPlasmaPreservation Types
FrozenDiagnoses
Coronary Artery DiseaseOther diagnosesPlatforms
ProteinHematology/ auto analyzerPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Preaquisition Diagnosis/ patient condition Antiphospholipid antibody syndromeDeep vein thrombosisOther diagnosesRecurrent spontaneous abortionPreaquisition Other drugs Low molecular weight heparinUnfractionated heparinBiospecimen Acquisition Anticoagulant Citrate-theophylline-adenosine-dipyridamoleSodium citrateBiospecimen Aliquots and Components Aliquot size/volume 6:1 blood to anticoagulant ratio9:1 blood to anticoagulant ratio